CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also announced...
NEURO-PAIN MEDICAL CENTER is recruiting for a clinical research study to evaluate an investigational medication in people diagnosed with Parkinson’s disease who are experiencing symptoms such as seeing things/hearing things that may not actually be there. The study...
Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced that the first patient has been dosed in the Company’s...
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Data Presented at ID Week...
Well Capitalized to Complete Current Ampligen Clinical Trials Following $10M in Capital Raises Plus $15M Recently Awarded by DOD to Roswell Park and Moffitt for Ampligen-Related Breast Cancer Trials OCALA, FL / ACCESSWIRE / October 7, 2019 / AIM ImmunoTech Inc. (NYSE...
WESTON, Fla.–(BUSINESS WIRE)–ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced full enrollment of its Phase 2b study. On October 3, 2019, ILiAD...
Email
Text